title: Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
abstract: To evaluate the efficacy and toxicity profiles of everolimus in Japanese patients with renal angiomyolipoma associated with tuberous sclerosis complex.
  
  
  
  Patients with a 4-cm or larger angiomyolipoma meeting the diagnostic criteria of tuberous sclerosis complex were selected as participants of our investigation. In each case, we assessed tuberous sclerosis complex-associated symptoms, the treatment effect and adverse events. The treatment effect was evaluated by measuring the tumor volume reduction rate using abdominal computed tomography or magneitc resonance imaging. Adverse events were investigated using CTCAE v4.0-JCOG. The dose of everolimus was set at 10 mg once a day for adults. For childhood angiomyolipoma, everolimus administration was initiated at a dose of 5 mg once a day. Blood everolimus level was measured, and the dose was adjusted to maintain this within a range of 5-15 ng/mL.
  
  
  
  The angiomyolipoma volume decreased in 46 of 47 cases, and the mean reduction rate for all cases was 60% in 12 months. The angiomyolipoma volume markedly decreased in the first 3 months, and the size leveled off after 6 months. The main adverse events related to everolimus treatment were stomatitis (91%) and irregular menstruation (65%). Grade 3 or severer adverse events were noted in three cases (6%). All patients developed some adverse events in the first 6 months. The incidence markedly decreased to 40-50% after 13 months.
  
  
  
  The tumor volume-reducing effect of everolimus in a Japanese population was equivalent to or higher than that in Western populations. A wide variety of everolimus treatment-related adverse events can be observed, but most cases are very mild. Special attention should be given to stomatitis, irregular menstruation and interstitial lung disease as adverse events.
authors.affiliation: Department of Urology, JR Tokyo General Hospital, Tokyo, Japan. hatano-t@jreast.co.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Hatano
authors.affiliation: Department of Urology, JR Tokyo General Hospital, Tokyo, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Chikaraishi
authors.affiliation: Department of Urology, JR Tokyo General Hospital, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Inaba
authors.affiliation: Department of Urology, JR Tokyo General Hospital, Tokyo, Japan.
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Endo
authors.affiliation: Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Shin
authors.initials: S
authors.lastname: Egawa
mesh_terms: D018207:Angiomyolipoma / Q000150:complications / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D014402:Tuberous Sclerosis / Q000150:complications*
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus
keywords: everolimus; mammalian target of rapamycin inhibitor; oncological outcome; renal angiomyolipoma; tuberous sclerosis complex